SAKK 23/16 TAXIS

Surgical lymph node removal with the option of “extensive operation” or “radiotherapy” in breast cancer patients with existing axillary lymph node involvement

Coordinating Investigator

Walter Weber

Leiter Brustzentrum

In this trial we are investigating the efficacy of radiotherapy compared to surgery in the treatment of breast cancer with axillary lymph node involvement. We are conducting this trial to discover the most effective treatment with the fewest side effects.

The trial schedule is as follows: A limited number of affected lymph nodes and the sentinel nodes will be surgically removed from all patients. The patients will then be assigned to one of two groups on a random basis (randomized trial).

In one group, the remaining lymph nodes in the axilla will be removed. This corresponds to the standard treatment for effectively preventing recurrences in the axilla. However, side effects – permanent in some cases – persist in about one quarter of patients. Such effects include impaired sensation, chronic pain, restricted movement in the shoulder and swelling of the arm, known as lymphoedema. In the other group, the axilla will be irradiated. This treatment can sometimes be just as effective as the treatment for the first group and cause fewer side effects. If the benefit of the radiotherapy is confirmed in this trial, this may become the new standard treatment for patients with this disease.

This trial will be conducted at numerous centers in Switzerland and other countries. In total, we plan to recruit 1,500 patients (women and men with breast cancer) over a period of just over 5 years. The whole trial will last for about 25 years, including the follow-up period. Medical visits will take place at frequent intervals at the start of the trial and then annually from the third year of participation.

This important phase III trial will be conducted with generous support from Fond’action contre le cancer, Krebsliga beider Basel, Stiftung Krebsforschung Schweiz, and The Rising Tide Foundation for Clinical Cancer Research.

Accrual is planned until end of 2023, with a duration until the primary endpoint of 11 years.

Fond’action contre le cancer

Kliniken

Ospedale MultiMedica Castellanza

Further Studies: Breast cancer

SAKK 66/22

A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

Recruitment completed

IBCSG 52-15 PALLAS

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Recruitment completed

IBCSG 67-22 PREcoopERA

A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

Recruitment completed

IBCSG 48-14 POSITIVE

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE).

Surgical lymph node removal with the option of “extensive operation” or “radiotherapy” in breast cancer patients with existing axillary lymph node involvement

Coordinating Investigator

Kliniken

Further Studies: Breast cancer

Triple-negative (hormone-independent) breast cancer, TNBC

Researchers are looking for a better way to treat ER+/HER2- early-stage breast cancer

Breast cancer: is surgery still necessary if tumor tissue can no longer be detected following chemotherapy?

Does doxycycline improve breast cancer treatment?

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE).